S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
NASDAQ:SWAV

ShockWave Medical - SWAV Stock Forecast, Price & News

$188.99
+6.95 (+3.82%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$179.48
$189.25
50-Day Range
$175.41
$253.60
52-Week Range
$113.36
$320.54
Volume
387,698 shs
Average Volume
467,193 shs
Market Capitalization
$6.83 billion
P/E Ratio
81.11
Dividend Yield
N/A
Price Target
$244.44

ShockWave Medical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
29.3% Upside
$244.44 Price Target
Short Interest
Healthy
3.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.73mentions of ShockWave Medical in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$14.45 M Sold Last Quarter
Proj. Earnings Growth
24.66%
From $2.96 to $3.69 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.14 out of 5 stars

Medical Sector

13th out of 1,029 stocks

Surgical & Medical Instruments Industry

2nd out of 105 stocks

SWAV stock logo

About ShockWave Medical (NASDAQ:SWAV) Stock

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Receive SWAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ShockWave Medical and its competitors with MarketBeat's FREE daily newsletter.

SWAV Stock News Headlines

Mergers and Acquisitions in 2023 Off To A Strong Start (SWAV)
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Shockwave Medical Down 7% After Neovasc Acquisition
Why Neovasc Shares Are Trading Higher Today
How Doug Godshall Ignited The Spark At Shockwave
Amedisys (AMED) Faces Macro Challenges, Margin Pressure
Teleflex (TFX) OEM Arm Grows, Supply Issue Persists
McKesson (MCK) Announces Availability of FDA-Accepted Drug
Here’s Why ShockWave Medical (SWAV) Outperformed in Q3
See More Headlines
Receive SWAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ShockWave Medical and its competitors with MarketBeat's FREE daily newsletter.

SWAV Company Calendar

Last Earnings
11/08/2021
Today
2/07/2023
Next Earnings (Confirmed)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SWAV
Fax
N/A
Employees
657
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$244.44
High Stock Price Forecast
$310.00
Low Stock Price Forecast
$165.00
Forecasted Upside/Downside
+29.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-9,140,000.00
Pretax Margin
20.75%

Debt

Sales & Book Value

Annual Sales
$237.15 million
Book Value
$6.85 per share

Miscellaneous

Free Float
34,732,000
Market Cap
$6.83 billion
Optionable
Not Optionable
Beta
0.97

Key Executives

  • Douglas Evan GodshallDouglas Evan Godshall
    President, Chief Executive Officer & Director
  • Mike Maszy
    Vice President-Operations
  • Daniel Puckett
    Chief Financial Officer & Secretary
  • Beaux Alexander
    Vice President-Clinical Affairs
  • W. Patrick Stephens
    Vice President-Research & Development













SWAV Stock - Frequently Asked Questions

Should I buy or sell ShockWave Medical stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ShockWave Medical in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWAV shares.
View SWAV analyst ratings
or view top-rated stocks.

What is ShockWave Medical's stock price forecast for 2023?

9 equities research analysts have issued twelve-month price objectives for ShockWave Medical's shares. Their SWAV share price forecasts range from $165.00 to $310.00. On average, they anticipate the company's share price to reach $244.44 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts price targets for SWAV
or view top-rated stocks among Wall Street analysts.

How have SWAV shares performed in 2023?

ShockWave Medical's stock was trading at $205.61 at the beginning of the year. Since then, SWAV stock has decreased by 8.1% and is now trading at $188.99.
View the best growth stocks for 2023 here
.

When is ShockWave Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our SWAV earnings forecast
.

How can I listen to ShockWave Medical's earnings call?

ShockWave Medical will be holding an earnings conference call on Thursday, February 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were ShockWave Medical's earnings last quarter?

ShockWave Medical, Inc. (NASDAQ:SWAV) released its quarterly earnings results on Monday, November, 8th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.12. The business had revenue of $65.16 million for the quarter, compared to analysts' expectations of $61.21 million. ShockWave Medical had a trailing twelve-month return on equity of 30.08% and a net margin of 20.48%. The company's revenue was up 232.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.38) earnings per share.

What guidance has ShockWave Medical issued on next quarter's earnings?

ShockWave Medical updated its earnings guidance on Wednesday, January, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $143.00 million-$144.00 million, compared to the consensus revenue estimate of $141.50 million.

What is Doug Godshall's approval rating as ShockWave Medical's CEO?

8 employees have rated ShockWave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

What other stocks do shareholders of ShockWave Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ShockWave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

When did ShockWave Medical IPO?

(SWAV) raised $75 million in an IPO on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ShockWave Medical's stock symbol?

ShockWave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Who are ShockWave Medical's major shareholders?

ShockWave Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (0.96%), Allspring Global Investments Holdings LLC (0.90%), New York State Common Retirement Fund (0.60%), Strs Ohio (0.24%), Fisher Asset Management LLC (0.22%) and TD Asset Management Inc (0.14%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sofinnova Capital Vii Fcpr and Trinh Phung.
View institutional ownership trends
.

How do I buy shares of ShockWave Medical?

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ShockWave Medical's stock price today?

One share of SWAV stock can currently be purchased for approximately $188.99.

How much money does ShockWave Medical make?

ShockWave Medical (NASDAQ:SWAV) has a market capitalization of $6.83 billion and generates $237.15 million in revenue each year. The company earns $-9,140,000.00 in net income (profit) each year or $2.33 on an earnings per share basis.

How many employees does ShockWave Medical have?

The company employs 657 workers across the globe.

How can I contact ShockWave Medical?

ShockWave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The official website for the company is www.shockwavemedical.com. The company can be reached via phone at (877) 775-4846 or via email at investors@shockwavemedical.com.

This page (NASDAQ:SWAV) was last updated on 2/8/2023 by MarketBeat.com Staff